Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   21:52
138,74 USD (+2,02%)
(+2,02%)   21:52

24 april 2024 · Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community · Persbericht

23 april 2024 · Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder · Persbericht

10 april 2024 · Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results · Persbericht

3 april 2024 · Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder · Persbericht

28 maart 2024 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults · Persbericht

11 maart 2024 · Neurocrine Biosciences to Participate at Virtual Investor Conferences in March · Persbericht

27 februari 2024 · Neurocrine Biosciences to Participate at Investor Conferences in March · Persbericht

7 februari 2024 · Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 · Persbericht

17 januari 2024 · Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results · Persbericht

2 januari 2024 · Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

5 december 2023 · Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia · Persbericht

1 december 2023 · Neurocrine Biosciences to Host Analyst Day on December 5, 2023 · Persbericht

13 november 2023 · Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation · Persbericht

9 november 2023 · Neurocrine Biosciences Provides Development Pipeline Update · Persbericht

8 november 2023 · Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia · Persbericht

8 november 2023 · Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference · Persbericht

2 november 2023 · Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023 · Persbericht

31 oktober 2023 · Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance · Persbericht

10 oktober 2023 · Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results · Persbericht

5 oktober 2023 · Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints · Persbericht

Mijn selecties